SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-055141
Filing Date
2024-05-01
Accepted
2024-05-01 06:02:12
Documents
14
Period of Report
2024-05-01
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2412887d1_8k.htm   iXBRL 8-K 22879
  Complete submission text file 0001104659-24-055141.txt   240035

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA otlk-20240501.xsd EX-101.SCH 3293
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE otlk-20240501_def.xml EX-101.DEF 26456
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20240501_lab.xml EX-101.LAB 35976
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20240501_pre.xml EX-101.PRE 25114
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2412887d1_8k_htm.xml XML 5037
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 24899815
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)